Efficacy of eculizumab in refractory life‐threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia

Eculizumab may be considered as an emergency therapeutic option in refractory life‐threatening warm autoimmune hemolytic anemia especially if direct antiglobulin test is positive for both IgG and C3d and after failure of all conventional treatments.

Detalles Bibliográficos
Autores principales: Gauchy, Anne‐Cécile, Hentzien, Maxime, Wynckel, Alain, de Marcellus, Victoire, Rodier, Cyrielle, Delmer, Alain, Quinquenel, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752594/
https://www.ncbi.nlm.nih.gov/pubmed/33363796
http://dx.doi.org/10.1002/ccr3.3250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752594/
https://www.ncbi.nlm.nih.gov/pubmed/33363796
http://dx.doi.org/10.1002/ccr3.3250

Ejemplares similares